Skip to content
Reflections of yellow marbles on metal holders
Reflections of yellow marbles on metal holders

Life Sciences

Our global Life Sciences practice comprises a multi-disciplinary team. We act for companies and their investors across the industry, including in the pharmaceuticals, biotech, veterinary, medtech, diagnostics and healthcare sectors.

The practice operates on a cross-border basis and covers the full spectrum of legal support. We advise on mergers and acquisitions, commercial transactions (including licensing and collaborations), IP (both contentious and non-contentious), capital markets and finance, regulatory and dispute resolution. Our international network ensures that we have a ready resource of expertise in a number of jurisdictions, including those in emerging markets, and that we are well positioned to advise on cross-border work.

We have won a reputation for providing far-sighted advice to some of the world’s leading life science companies – including GlaxoSmithKline, Pfizer, UCB, Merck, Bayer and Novartis.

News & insights

Image of a skyscraper with blue tinted windows

Publications: 08 JULY 2021

Dramatic pause in global Special Purpose Acquisition Companies (SPACs) clouds the outlook

The extraordinary boom in U.S. SPAC formations continued in Q1 but declined steeply from April onwards. Few believe the trend is over, but a period of greater uncertainty seems likely. SPACs are now…

Read more
close up of glaze building

Publications: 08 JULY 2021

Innovation and search for growth spark MedTech rebound

The postponement of non-urgent medical procedures in the early days of the Covid-19 pandemic led to a lull in MedTech transaction activity in the first half of 2020 but makers of medical devices…

Read more
Close up of a modern green glass and metal building

Publications: 07 APRIL 2021

Compelling signals from a recovering M&A market

The question at the end of 2020 was whether the strong recovery in M&A activity could be sustained in 2021.

Read more
Allen & Overy graphic

Publications: 21 DECEMBER 2020

Covid-19 coronavirus and global employment law: Managing your workforce throughout the pandemic – part 4

In the fourth in our series of webinars, members of Allen & Overy’s Global Employment team discussed the significant issues and challenges that employers need to prioritise in relation to managing and…

Read more

Recognition

Related links

Life Sciences Hub

We report on EU and national regulatory, compliance, intellectual property and transactional developments in the sector.

Read more

CRISPR microsite

The characterisation and optimisation of the CRISPR (also known as CRISPR-Cas) system for gene editing and other applications, is undoubtedly one of the most powerful and ground breaking advances in the history of biotechnology.

Go to microsite

Growth Capital microsite

Allen & Overy is an engaged and active player in the growth company ecosystem.

Go to microsite

Cannabis microsite

According to UN estimates, the global cannabis market is currently worth approximately USD150 billion annually. 

Go to microsite

Download our sector brochure

Life sciences A&O red molecules

An insight in to our Life Science and Healthcare sector 2021

Our global Life Sciences and Healthcare sector comprises a multi-disciplinary team. We act for companies and their investors across the industry, including in the pharmaceuticals, biotech, animal health, consumer health, med tech, and diagnostics sectors.

Related content

Global trends in merger control enforcement

Record levels in the first half of 2018 and considerable contraction in the second.